The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us